Rein Therapeutics Inc.
RNTX
$0.92
-$0.03-2.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.13% | 22.00% | 4.55% | 23.71% | 22.66% |
| Total Depreciation and Amortization | -- | -- | -- | -75.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -40.91% | -21.88% | 263.58% | -21.47% | 76.00% |
| Change in Net Operating Assets | 274.31% | 73.03% | -87.76% | -34.08% | -157.44% |
| Cash from Operations | 44.55% | 33.08% | 7.10% | 23.50% | -17.15% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -52.03% | 145,400.00% | -- | -88.70% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -52.04% | -- |
| Cash from Financing | 530.62% | 240,400.00% | 526.01% | -74.20% | -- |
| Foreign Exchange rate Adjustments | -- | -1,700.00% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 122.62% | 82.69% | 60.75% | -117.28% | -3.15% |